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CObjective: To determine the cost-effectiveness of fluoxetine and cog-
nitive-behavioral therapy (CBT) for major depression in Thailand.
Methods: A microsimulation model was developed to describe the
variation in course of disease between individuals. Model inputs
included Thai data on disease parameters and costs while impact
measures were derived from a systematic review and meta-analysis
of the international literature. Fluoxetine as the cheapest antide-
pressant drug in Thailand was analyzed for treatment of episodes
plus a 6-month continuation phase and for maintenance treatment
over 5 years of follow-up. CBT was analyzed for episodic treatment
and for 5-year maintenance treatment. Results are presented as cost
(Thai bahts) per disability-adjusted life-year (DALY) averted, com-
pared with a “do-nothing” scenario. Results: The cost-effectiveness
ratios of all interventions were below 1 time Thailand’s gross domes-
tic product of 110,000 bahts per capita. The uncertainty ranges O
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doi:10.1016/j.jval.2011.11.009round the cost-effectiveness ratios overlap: maintenance treat-
ent with CBT 11,000 bahts per DALY (8,000–14,000); episodic treat-
ent with CBT 23,000 bahts per DALY (10,000–36,000); episodic plus
ontinuation drug treatment 33,000 bahts per DALY (26,000–44,000);
aintenance drug treatment 38,000 bahts per DALY (30,000–48,000);
nd episodic drug treatment 42,000 bahts per DALY (32,000–57,000).
onclusions: CBT and generic fluoxetine are cost-effective treatment
ptions for both episodic andmaintenance treatment of major depres-
ion in Thailand. Maintenance treatment has the greatest potential of
ealth gain.
eywords: health economics, major depressive disorder, pharmaco-
herapy, psychotherapy.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Major depression has a large health and economic impact on
individuals and communities. Up to 15% of patients with de-
pression die from suicide over their lifetime [1]. By the year
2020, if the current demographic trends and epidemiological
transition continue, the burden of depression will increase to
5.7% of the global burden of disease, becoming the second lead-
ing cause of disability-adjusted life-years (DALYs) lost, eclipsed
only by ischemic heart disease in both males and females [2].
ccording to the Thai Mental Health Survey 2003, major depres-
ion was the most prevalent mental disorder in Thailand (3.2%;
5% confidence interval [CI] 2.9–3.5) [3]. Depressive disorder
lso imposes a significant burden in Thailand. It ranked as one
f the top 10 causes of DALYs lost in Thailand in 1999, coming
rst for females and fourth for males [4]. Depression is also a
ostly disease. The high costs are not only the direct treatment
osts, but there is also a large contribution from indirect costs
ncluding absenteeism, loss of opportunity, and productivity [5].
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Published by Elsevier Inc.Previous studies have found that there are a variety of treat-
ment options for improving the quality of life and social function
of patients who havemajor depression [6–8]. In addition, effective
reatment can decrease the financial burden of illness by reducing
he direct and indirect costs associated with depression [9]. Effec-
ive interventions include antidepressant drugs and various
ethods of psychotherapy. The first-line treatment for most peo-
lewith depression today consists of antidepressant drug therapy,
sychological interventions, or a combination of the two. Among
he psychotherapeutic approaches, cognitive-behavioral therapy
CBT) is an intervention recommended by clinical practice guide-
ines for the treatment of depression [7,8]. In Thailand, these in-
erventions are currently recommended by the clinical practice
uidelines for the treatment of major depressive disorder of the
oyal College of Psychiatry of Thailand and the Psychiatric Asso-
iation of Thailand [10]. CBT, however, is currently only sporadi-
ally available in Thailand. In general, the country has very few
eople with any psychotherapeutic skills. There are a number of
ntidepressant drugs in Thailand. Only two of them have generic
ersions available, fluoxetine and sertaline.
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S4 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 – S 8Despite there being a range of options for treating patientswith
depressive disorders, even in high-income countries only one-
third of patients receive effective treatments [11,12]. Even re-
cently, the health insurance schemes that covered all Thai peo-
ple—6 million (9%) covered by the Civil Servant Medical Benefit
Scheme, 10 million (16%) covered by the Social Health Insurance
scheme, and the rest of the population (47 million) covered by the
Universal Coverage scheme [13]—estimated that only 4% of psy-
chiatric patients received treatment [14]. In Thailand, resources
currently allocated to meet the needs of patients with mental dis-
order are scarce [15]. Given finite resources in mental health per-
sonnel and budget, economic evaluation can help to determine
the most cost-effective interventions among numerous interven-
tion options available. Such evidence can help policy decision
makers set priorities in terms of budget allocation [16].
Two articles have reviewed the effectiveness of CBT by newly
trained Thai CBT therapists in Thai depressive patients [17,18].
othwere outcomes of a project to trainmental health profession-
ls in the treatment of major depression by CBT. In the first phase,
0 experienced mental health professionals were trained in a
-day workshop by a qualified trainer from the United Kingdom.
ll trainees received at least eight sessions of supervision from
wo qualified Thai therapists. During the training, a Thai manual
f CBT for depression was developed. In the last phase of the proj-
ct, a 16-week, open-label study of the efficacy and acceptability of
BT in patients with major depression not responding to 4-weeks
f treatment with fluoxetine was carried out.
The first study [18] reported outcomes in 15 patients treated
y four newly trained therapists. Overall, the treatment pro-
ram seemed effective in alleviating depression (13 of the 15
atients improved significantly), and patient satisfaction with
reatment was high. Fifty-seven percent of patients, however,
topped treatment before week 12; only one completed all the
6 sessions. The authors concluded that CBT efficacy as evident
n Western studies can be generalized to the Thai context. Nev-
rtheless, the high discontinuation rate suggests that patients
ay prefer a shorter duration of treatment. The other study [17]
eported that all 10 patients, of three newly trained therapists
rom this same CBT training program, responded by week 12
nd 70% of them were in remission by week 12. Neither study
ad a control group and therefore provide insufficient evidence
f effectiveness.
There is only one cost-effectiveness study of drug treatment of
ajor depressive disorder in Thailand. It concluded that escitalo-
ram was more cost-effective than fluoxetine and venlafaxine,
ut it did not consider the availability of a cheap generic version of
uoxetine [19]. There are no economic evaluations of psychother-
py in Thailand. Our study aims to inform policymakers of the
ost cost-effective intervention formajor depression in Thailand.
Methods
Cost-effectiveness analysis is a method of assessing the health
consequences relative to the costs of different health interven-
tions. It is used to identify health interventions that yield the high-
est benefit in health outcomes per monetary unit of health expen-
diture [20].
Framing and design of the analysis
This study adopted a “health sector” perspective, arguing that it is
most suitable to policymakers as part of decisionmaking in health
resource allocation. This perspective concerns the health-related
costs borne by government and by individuals including time and
travel costs. The comparator was a hypothetical “do-nothing” sce-
nario-based on the generalized Cost-Effectiveness Analysis
framework [21]. The target population in this study was those in ithe Thai population in 2005 experiencing a major depressive epi-
sode. The time horizon for evaluating the benefits and costs of
interventions for depression was over a 5-year follow-up period.
This time horizon was considered appropriate for tracking the
costs/cost offsets and consequences associated with the selected
interventions as therewasno information on the longer-termcon-
sequences of these interventions beyond 5 years. In addition, the
natural history of depression can be reasonably described over a
5-year period, but there is a lack of data to accurately describe the
course of major depression over a lifetime.
A 3% discount rate that matches the rate chosen in the Thai
burden of disease study [4] was applied to both costs and benefits.
t is also the rate of discounting recommended by a consensus
anel of health economists in the United States [22], and it was in
he range of 3% to 5% recommended by economic evaluation
uidelines in Thailand [23].
Description of interventions
Pharmacological interventions and CBTwere selected for analysis
by the steering committee and the expert advisory group for men-
tal health in the Setting Priorities using Information on Cost-Effec-
tiveness (SPICE) project, which was a collaborative project be-
tween the Ministry of Public Health, Thailand, and the University
of Queensland, Australia. We undertook the current study as part
of the SPICE project, which aimed to address key information gaps
on burden of disease and cost-effectiveness across multiple dis-
ease areas in Thailand, with regard to policy concerns and techni-
cal rationality. The SPICE project included a cause of death study
that aimed to improve the quality of cause of death statistics by
deriving a “best” estimate of true cause-specific mortality in Thai-
land based on verbal autopsy interviews of 11,000 deaths and re-
view of available medical records [24–27].
The interventionswere classified by three phases of treatment:
First, the acute or episodic phase is the time period from the initi-
ation of treatment to remission (i.e., decrease in depressive symp-
toms to “normal”), which usually lasts between 8 and 12 weeks
[12]. Second, the continuation phase is the period following the
episodic phase for preventing relapse (i.e., the return to major
depression). At least 6-months continuation therapy has been rec-
ommended by guidelines for the treatment of major depressive
disorder [8,28]. Third,maintenance treatmentmay be givenduring
a 5-year period following an episode to prevent recurrence (i.e., a
new episode of major depression following recovery).
The drug interventions for major depression include the older
tricyclic antidepressants, amitryptyline; the newer serotonin re-
uptake inhibitors, fluoxetine, sertaline, and escitalopram; and the
newer serotonin norepinephrine reuptake inhibitor, venlafaxine.
Generic serotonin reuptake inhibitors cost less than 10% of the
cost of patented medications in Thailand. Meta-analyses show no
difference in efficacy between antidepressant drugs [29,30]. There-
fore, we analyzed generic fluoxetine only as the lowest cost anti-
depressant and the most commonly prescribed serotonin re-
uptake inhibitor in Thailand [31].
CBT is a nonpharmacological intervention that is effective in
the treatment of depression alone or combinedwith drug therapy.
A course of CBT during or following an acute episode has been
found to prevent relapse for up to 1.5 years after an episode [32]
nd to further reduce recurrence if booster sessions are given as
aintenance treatment [33,34]. CBT is a highly structured ap-
roach to psychotherapy with a shorter duration than most other
herapies. The assumption of CBT is that emotional and behav-
oral problems are caused by cognitive or thought dysfunction.
BT is based on collaborative work between the therapist and the
lient. The therapist helps the client to identify emotions or feel-
ngs, negative automatic thoughts, and schema or core beliefs.
his leads to modification of automatic thoughts and core beliefs
n the end [35].
fS5V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 – S 8Modeling
The diseasemodel has amathematical structure that represents the
health outcomes of 8000 hypothetical patients under five scenarios:
episodic drug treatment, continuation drug treatment,maintenance
drug treatment, episodic CBT treatment, and maintenance CBT
treatment. We chose this hypothetical number because it was
enough to get a stablemodel that reflects the variability in the course
of thedisorder.Asmajordepression is a recurrentdisorderwith large
variations in duration of episodes and time to the next episode, a
discrete event simulation model was chosen to evaluate the costs
and consequences of interventions for major depression.
Themodel structure was based on themodel developed for the
Assessing Cost Effectiveness of Mental Health (ACE-MH) study in
 Set sim
 Initialize
 Initialize
 Sample time 
 Sample proba
Sample time 
Elapsed t
If elapsed time<0 then 
and truncate “the samp
event” so that “total tim
with time horizon( in the
* simulation clock measures        
continuous time across all states 
(depressive state and symptom-
free state) 
If elapsed time >0 
Fig. 1 – Graphical representation of the algorithm of discrete
Caro [39]).
Table 1 – Effectiveness parameter values and sources of
information.
Parameter Value
(95% confidence interval)
RR suicide on treated vs. untreated
depression
1.80 (1.60–2.00) [37]
Effect size of antidepressant drugs 0.32 (0.25–0.40) [39]
Effect size of CBT 0.77 (0.44–1.10) [11]
RR relapse during 6-mo continuation
of drug treatment
0.42 (0.32–0.56) [11]
RR relapse in 18 mo following CBT 0.64 (0.51–0.78) [11]
RR relapse for drug/CBT
maintenance treatment
0.44 (0.39–0.49) [11]CBT, cognitive-behavioral therapy; RR, relative risk.Australia [36]. The ACE-MH model only derived an average num-
ber of episodes and proportion of follow-up time with depression
from microsimulation and applied these averages as inputs to a
deterministic cost-effectiveness model. This study uses simula-
tion modeling of individual-level data all the way through to the
determination of costs and benefits.
This model was constructed in Microsoft Excel by using the
add-in Ersatz software for uncertainty analysis [37]. Each individ-
ual patientwas simulated over a 5-year period through the natural
history of depression (age, sex, and suicide risk). The model used
continuous time; thus, it was not restricted by a fixed cycle length.
Time to next eventwas determined stochastically from a specified
distribution. Each individual could have periods of depression and
episode-free periods of varying lengths. The algorithm of this dis-
crete event simulation model as shown in Figure 1 was adapted
rom Lay et al. [38] and Caro [39].
Initialization 
n clock *                                     
em state: start with depressive episode 
t list 
Determine next event 
ission/recovery  
 of suicide 
apse/recurrent event (i.e. return to disease)
Update clock 
 time horizon (5 yrs) – Sampled time to event   
imulation 
me to 
psed” fits 
s period) 
If elapsed time=0 or death by 
suicide then end simulation 
End Simulation 
 Compute final estimates 
 Generate reports 
nt simulation model (adapted from Le Lay et al. [38] and
Table 2 – Cost input parameter values and sources of
information.
Parameter Value (THB)
(uncertainty range)
Psychiatric outpatient operating cost
per visit
529 (436–585) [45]
Drug (fluoxetine) cost per day 2 (1–3) [46]
Time cost per visit 37 (46–28) [48]
Travel cost per visit 24 (29–18) [49]ulatio
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We used data for the prevalence of major depression by age and
sex from the National Mental Health Survey in 2003 [3] and used a
lognormal distribution of data from international follow-up stud-
ies to mathematically describe the variation in length of episodes
( 2.05,  1.60) and time between episodes ( 2.35,  3.88) (12). In
ddition, we assumed a minimum of 2-week duration of an epi-
ode as stipulated by the International Statistical Classification of Dis-
ases, 10th Revision, and the Diagnostic and Statistical Manual of Men-
al Disorders, Fourth Edition, diagnostic criteria and applied a rule of
minimum of 8 weeks free of depression before it can be called a
ew episode of depression rather than a relapse back into the
ame episode [40].
During a depressive episode, patients are at increased risk of
uicide. We used the relative risks of suicide with depression of
5.7 (95% CI 11.9–20.3) for males and 27.8 (95% CI 21.8–34.8) for
emales from a meta-analysis [41]. These relative risks along with
he prevalence of major depression in Thailand were applied to
he total number of suicide deaths from the SPICE cause of death
tudy to calculate suicide deaths attributable to depression by age
nd sex. As part of fatal health consequences,we applied a relative
isk of suicide for those on treatment versus those not on antide-
ressant treatment [42] to the number of suicide deaths attribut-
ble to depression by age and sex to determine a yearly suicide risk
n those with treated and untreated depression.
Estimating intervention effectiveness
Themeasure of health gain chosen was the DALY. Health gain from
the averted number of suicide deaths was estimated by multiplying
Table 3 – Values and assumptions of number of visits
for interventions.
Intervention Number of visits per
year (uncertainty
range)
Source
Episodic drug
treatment
10 (8–12) Expert advice*
Continuation drug
treatment
7 (6–8) Expert advice*
Maintenance drug
treatment
5 (4–6) Expert advice*
Episodic CBT treatment 10 (8–12) Expert advice*
Maintenance CBT
treatment
5 (4–6) Expert advice*
CBT, cognitive-behavioral therapy.
* From the expert advisory team for mental health in the Setting
Priorities using Information on Cost-Effectiveness project.
Table 4 – Total costs, DALYs averted, and cost-effectivenes
with depression.
Intervention Total costs (million bahts)
(95% uncertainty interval)
Episodic drug treatment 370 (280–520)
Continuation drug treatment 460 (350–600)
Maintenance drug treatment 680 (500–900)
Episodic CBT treatment 290 (180–410)
Maintenance CBT treatment 210 (1,600–300)
Note: All estimates rounded to two significant digits.
CBT, cognitive-behavioral therapy.each death with the remaining discounted health-adjusted life ex-
pectancy based on the life table generated for Thailand in 2005 from
the SPICE cause of death study and the rates of prevalent years lived
with disability from the 1999 Thai Burden of Disease study [4]. This
rate of prevalent years lived with disability was taken as a proxy for
the probability of nonfatal health loss by age and sex in 2005.
Nonfatal health outcomes were calculated in a number of
steps. First, we translated pooled effect sizes (ESs) for each inter-
vention from various trials into a change in the disability weight
(DW) [43]. Because a number of scales are used for measuringmen-
tal health outcomes in trials, the ES of interventions was pooled as a
standardizedmeandifference [44].Weused the ESof the antidepres-
sant drugs from theKirsch et al. [45]meta-analysis of data submitted
to the Food and Drug Administration of the United States, which
avoided the publication bias affecting other meta-analyses. We ad-
opted an estimate of the average change in DW per ES calculated in
the Australian ACE-MH study [46]. This was based on a DW of un-
treated depression (0.35) and a conversion factor of 0.16 (95%CI 0.14–
0.17) per unit of ES adopted from the study of Sanderson et al. [47].
In addition to reducing disability during a depressive episode,
drug interventions lower the risk of relapse if given as continu-
ation and maintenance therapy. These data and the ESs for CBT
came from meta-analyses conducted for the ACE-MH study [12]
based on a previously published meta-analysis by Geddes and
colleagues [48]. The effectiveness measures are summarized in
Table 1.
Health benefits of interventions were ignored in patients not
adhering to drug therapy or CBT. Adherence across all antidepres-
0
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Fig. 2 – Cost-effectiveness plane for depression
interventions. AD, antidepressant; CBT, cognitive-
behavioral therapy; DALY, disability-adjusted life-year;
GDP, gross domestic product.
ios of depression interventions per 100,000 individuals
LYs (95% uncertainty interval) Cost-effectiveness ratio
(95% uncertainty
interval)
9,000 (8,000–11,000) 42,000 (32,000–57,000)
14,000 (11,000–19,000) 33,000 (26,000–44,000)
18,000 (15,000–24,000) 38,000 (30,000–48,000)
13,000 (9,000–20,000) 23,000 (10,000–36,000)
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S7V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 – S 8sants of 41% (95% CI 37%–46%) came from our own study, which
evaluated an electronic prescription database of depressive pa-
tients in a psychiatric hospital in Thailand [31]. In the absence of
data, we assumed the same adherence for CBT. The model also
took into account a lag before patients seek treatment. Expert
opinion sought for theACE-MH study suggested that the lag period
for treatment of depression is 2 to 4 weeks, and Thai experts
agreed with this estimate.
Estimating intervention costs
Operating costs of an outpatient unit were derived from a study of
the Department of Mental Health in 2000 [49].The cost of drugs
was estimated from the drug price list of the Medical Information
Center, Department of Health Service Support, Ministry of Public
Health in 2005 [50]. We used the consumer price index [51] to ad-
just costs in other years to those in 2005. The cost of CBT was
calculated from the number of visits multiplied with the unit cost
per visit for outpatients. Time cost was assumed to be 25% [52] of
ersonal income per capita in Thailand in 2005 [53], and travel cost
as calculated from the average cost of the return trip to the hos-
ital by public transport from a Thai study [54]. Details of all costs
re described in Table 2. The assumptions of numbers of visits per
ear for drug treatment and CBT are described in Table 3.
Cost-offsets (the reduction in hospital costs as a direct result of
psychiatric treatment) were not included. Although there is evi-
dence to support cost-offsets in other areas of psychiatric care,
information of cost-offsets related to depression treatment is less
clear [55–58].
Sensitivity and uncertainty parameters
The uncertainty in this study includes first-order and second-or-
der uncertainty. First-order uncertainty analysis simulated the
course of disease in a hypothetical cohort of 8000 individuals. The
second-order analysis involved a multivariate probabilistic
Monte Carlo simulation of 1000 iterations of the model to quan-
tify the distribution in the cost-effectiveness ratios propagated
from the uncertainty in the input data as listed in Tables 1 to 3.
Uncertainty analyses were carried out in Excel with the Ersatz
software add-in program (www.epigear.com).
Results
The results are presented as cost-effectiveness ratio in Thai bahts
per DALY averted (Table 4).
Maintenance CBT had the lowest cost and averted the largest
number of DALYs. Maintenance treatment with drugs cost three
times more than CBT maintenance treatment. There was consid-
erable overlap in uncertainty between the cost-effectiveness ra-
tios (Table 4 and Fig. 2).
Discussion
The average cost-effectiveness ratios of all interventions were be-
low 1 time the GDP of 110,000 bahts per capita in Thailand, a level
recommended as a cutoff for “very cost effective” interventions
[59].
CBT and generic fluoxetine are cost-effective treatment op-
tions for both episodic and maintenance treatment of major de-
pression in Thailand. Maintenance treatment has the greatest po-
tential of health gain.
As the large majority of depressive patients have multiple ep-
isodes over their lifetime, there are strong recommendations to
treat major depressive disorder as a chronic episodic disease
[8,28]. Hence, most people with major depression should receive
longer-termmedication treatment or psychotherapy during whatare called “continuation” or “maintenance” periods to prevent re-
lapse and recurrence of the disorder.
CBT is currently only sporadically available in Thailand. CBT
is not part of psychology or psychiatry training programs. There
also is a lack of mental health personnel, especially psychia-
trists and psychologists, who would be expected to deliver CBT
in Thailand. It may be more feasible and would be less costly to
train psychiatric nurses as CBT therapists rather than psychia-
trists or psychologists.
Strengths of this analysis include using the microsimulation
model that can represent the natural history of depressive dis-
order as a chronic episodic disease. It allowed us to track all
patients as individuals taking into account the wide variation in
the length and frequency of episodes. The efficacy data of anti-
depressants are from a meta-analysis that took into account
unpublished data from pharmaceutical companies reported to
the Food and Drug Administration, avoiding the publication
bias that affects meta-analyses of published trials. The majority
of published studies were conducted by pharmaceutical com-
panies with a vested interest.
The main limitation of this study was the measurement of the
health benefit for each of the treatment options. There is no infor-
mation on the benefit of these interventions for major depression
in Thailand. We therefore relied on data from international meta-
analyses. The ES of interventions from clinical trials may not di-
rectly translate into effectiveness. The generalizability of the ef-
fectiveness measures, particularly for CBT, has not been
established. Psychological interventions under routine health-
care circumstances in Thailand may work differently from how
they work in different countries because of differences in health
services, culture, lifestyles, and beliefs [60].The cost of CBT did not
take into consideration starting-up costs, and so this can lead to an
underestimation of the implementation costs in our study. If Thai-
land would chose to implement CBT as a treatment option for
patients with major depression it would need to consider the cost
of health personnel training and the cultural factors that may in-
fluence its effectiveness. We recommend future research on the
efficacy and applicability of CBT or other psychosocial interven-
tions in the Thai context.
The results of this cost-effectiveness analysis indicate that CBT
could be a cost-effective treatment option in Thailand and that it
potentially can be more effective than drug treatment of major
depression, albeit under a series of assumptions regarding its ef-
ficacy in Thailand.
Source of financial support: Thisworkwas completed as part of
the Setting Priorities using Information on Cost-Effectiveness
project, funded by theWellcome Trust, UK (grant number 071842/
Z/03/Z) and the National Health and Medical Research Council of
Australia (grant number 301199).
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